MorphoSys
Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU
Phil Taylor
CAR-T therapies, EU, Incyte, MorphoSys, non-Hodgkin lymphoma, regulatory approval, tafasitamab
0 Comment
MorphoSys offers $1.7bn for Constellation, but investors see stars
Phil Taylor
Constellation Pharmaceuticals, Haematology, M&A, MorphoSys, myelofibrosis, Oncology, solid tumours
0 Comment
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody
Richard Staines
cancer, DLBCL, Incyte, MorphoSys, non-Hodgkin lymphoma
0 Comment
News/ News/ News/ Oncology/ R&D
MorphoSys gets $750m from Incyte for anti-CD19 cancer drug
Phil Taylor
antibody, Incyte, MorphoSys, non-Hodgkin lymphoma, Oncology
0 Comment
Novartis’ $100m bet on eczema drug fails as MOR106 development ends
George Underwood
atopic dermatitis, eczema, Galapagos, MorphoSys, Novatis
0 Comment
Novartis pays up to $1 billion for potential eczema drug
Piotr Wnuk
dermatology, Galapagos, immunology, MOR106, MorphoSys, Novartis
0 Comment